Leap Therapeutics @LeapTherapeutic
Leap Therapeutics is developing novel cancer drugs. leaptx.com Cambridge, MA Joined October 2015-
Tweets100
-
Followers716
-
Following9
-
Likes4
We’re excited to announce a $40 million equity financing. Thank you to our strategic and institutional investors for supporting our mission to develop DKN-01 to treat GI cancer patients around the world. investors.leaptx.com/news-releases/…
March is #ColorectalCancerAwarenessMonth. Through our DeFianCe Phase 2 CRC clinical trial, we're reminded of the unmet medical need of these patients and the dedication from our clinical sites and physicians aiming for better outcomes. leaptx.com/programs/color…
Reminder to join Drs. Pelster & Wainberg today at 8:30 AM ET, for their firsthand accounts on DeFianCe, our 2L CRC trial of DKN-01 in combination with Bevacizumab and chemo. Link here: edge.media-server.com/mmc/p/q5zrz568
Join us @ASCO #GI24 for updates on Part A of our DeFianCe #colorectalcancer study at Moscone West on Jan 20th from 6:30-9:30AM PST at poster G8. Also, tune in on Jan 23, 8:30 am ET to hear insights from the treating physicians. Details and links: investors.leaptx.com/news-releases/…
Our CEO, Doug Onsi, is presenting now in the Borgia room, Westin St. Francis. Tune into the webcast linked below for critical updates! #JPM2024 investors.leaptx.com/news-releases/…
Join us @jpmorgan’s 42nd Annual Healthcare Conference, 1/10/24, 1:30pm PT, to hear from our CEO Doug Onsi on Leap and our lead program, DKN-01. #JPM2024 investors.leaptx.com/news-releases/…
For more background on DKN-01 and our DeFianCe study in #colorectalcancer patients, read this interview with Dr. John Strickler of @DukeU from earlier this year. Making a difference for CRC patients is our mission at Leap. targetedonc.com/view/defiance-…
DKN-01 is moving into a second randomized controlled trial! This time in #ColorectalCancer patients. Early efficacy data and high investigator/patient enthusiasm mark another milestone for DKN-01. Thank you to everyone involved in the DeFianCe study. investors.leaptx.com/news-releases/…
Congratulations to our Leap Board member, @drwilliamli, on his new book Eat to Beat Your Diet!
Today at #ASCO2023, updated data from Part A of the DisTinGuish Study of DKN-01 + @BeiGeneGlobal’s tislelizumab + chemo in #gastriccancer was presented as a poster and in a discussion session. leaptx.com/wp-content/upl…..
Join us at #ASCO2023 as we present updates from Part A of the DisTinGuish Study! Dr. Sam Klempner will be sharing insights on DKN-01 + @BeiGeneGlobal’s tislelizumab & chemo in #gastriccancer at the poster and discussion session on June 5th, 11:30 AM CT. investors.leaptx.com/news-releases/…
Join us in Chicago on Monday, June 5 at #ASCO23 for a presentation and discussion of long-term follow-up data from Part A of our ongoing DisTinGuish study of DKN-01 in combination with @BeiGeneGlobal’s tislelizumab and chemo in 1L gastric cancer patients. investors.leaptx.com/news-releases/…
Our DeFianCe study aims to address the unmet medical need of CRC patients who have low response rates and PFS after 1L therapy. Part A has enrolled 33 patients to evaluate the efficacy of DKN-01, our anti-DKK1 antibody, as a potential new therapy. investors.leaptx.com/news-releases/…
Check out our latest publication which demonstrates that DKK1 is a predictive biomarker for clinical response in Endometrial Cancer (EC) and suggests DKN-01 is a promising therapy for DKK1 high EC patients. leaptx.com/wp-content/upl…
Thank you @Nasdaq for spreading the news of our Flame Biosciences acquisition, which brought 3 exciting pipeline assets; FL-301 CLDN18.2 mAb, FL-302 CLDN18.2/CD137 bispecific, and FL-501 GDF15 mAb as well as $50m in cash.
We are pleased to announce our acquisition of Flame Biosciences bolstering our innovative oncology pipeline. investors.leaptx.com/news-releases/…
Join us this Thursday at #SITC22 to hear about our DKN-01 preclinical colorectal cancer data and for an update on our ongoing DisTinGuish gastric cancer clinical trial: DKN-01 in combination with @BeiGeneGlobal's tislelizumab. investors.leaptx.com/news-releases/…
We are excited to announce the first patient has been enrolled into our randomized phase 2 DeFianCe study of DKN-01 in combination with bevacizumab and chemo for the 2nd line treatment of colorectal cancer. investors.leaptx.com/news-releases/…
Learn more about DKK1 and the mechanism of action of DKN-01 in #gastriccancer. Check out this new publication on DKK1’s multi-pronged role in suppressing anti-tumor immunity, making it a promising target for enhancing PD-1-based therapy. aacrjournals.org/cancerimmunolr…
BioEternalDamnation P.. @pawcio2009
13K Followers 700 Following Biosquidgames organizer. I jinx for living. 🇵🇱🇨🇦⚽️📈🎣🚴♂
`((,(Dieter 'Hovekamp.. @dhovekamp42
4K Followers 2K Following born to be me, expect the worst - go for the best { views are my own - tweets are not advice }
Charles Gordon @princetongb
4K Followers 1K Following We cannot direct the wind, but we can adjust the sails... Family Office. Founder Princeton Biomedical Consul. LLC.
Benchpressers @Benchpressers
2K Followers 5K Following Faith, Family, Stocks & Sports. God, $pdsb, Titans, Battlehawks, Illini, Salukis, Mo St Bears, Cardinals & Blues all day.
Wayne @wyv_123
2K Followers 5K Following 🐭Expressed opinions are my own & not investment advice. Retweets/Likes are not endorsements. 1 Corinthians 16:13-14
Kevin Wolcott @Kevin_W81
12K Followers 708 Following Best biotech trader in Irvine, CA. Champion table tennis player & sailing aficionado. 185 yrs of experience.
BeiGene @BeiGeneGlobal
5K Followers 285 Following We’re a global oncology company bringing innovative medicines & making them more accessible to patients worldwide. Community guidelines: https://t.co/bZCHuaXk0s
Greg W. 🛰🅰️ @grw1177
691 Followers 728 Following Sometimes you're the windshield, sometimes you're the bug : Sick of politics - they're all criminals : I value my Twitter friends : Take care of yourselves
Not Seeking Bailout @NotJanetYellen7
814 Followers 2K Following JD/PHD Runner/fitness/micro/small cap/bio investor Opinions are my own-not investor advice-DYODD #Gold #metals ML/ #AI #longevity #mentalhealth #cannabis #macro
Vee @ramanveena
355 Followers 85 Following Mom, active stock investor/trader, Information technology professional, IT consulting business partner and a proud Indian American.
albainbridge @albainbrid64404
1 Followers 3 Following
Lisa Volonino @lisa_desmarais3
12 Followers 211 Following
Andy Miller @amiller
35K Followers 960 Following Now: CEO/Founder @NRGgg, @SFShock, @hometap Was: CEO Quattro Wireless; VP Mobile Advertising Apple
Miĥaelo @mihxaelo
1 Followers 21 Following
Yousef @Josephissa84
191 Followers 965 Following Investor - Quantum physics amateur(self-taught) and lover of science and technology
RyonBio @RyonBio
467 Followers 2K Following Welcome to RyonBio’s Twitter account! We are a professional manufacturer and trader of plant extracts, nutritional supplements and other ingredients in China.
Joe Zerella @JoeZerella
106 Followers 2K Following UConn Huskies, Hartford Hawks, and Monmouth University fan. UConn alum. #BleedBlue #3PEAT
GreenPollex @GreenPollex
105 Followers 531 Following
drfeelgood @drfeelgood049
100 Followers 1K Following Dr. Selcuk Seber Medical Oncologist Tekirdag Namık Kemal University time spender,IO, performing precision oncology in a low resource enviorment
JCM @JMigyanka
14 Followers 27 Following
Watson Genomics @WatsonGenomics
61 Followers 1K Following
RQMIS Inc. @rqmis_inc
385 Followers 2K Following RQMIS provides focused comprehensive regulatory, quality & clinical consulting to the global medical device, pharmaceutical, nutraceutical & cosmetic industries
SB @ScottBooz
0 Followers 679 Following
Bill @Kate42131055358
34 Followers 307 Following thinking elon ought to use AI to remove creeps sending messages and SOMEHOW GETTING EMAIL’s they should have no way of getting that info..UNLESS employed
Joseph Sponzo @JosephSponzo
1 Followers 17 Following
Thomas Harriman @Tharriman9
5 Followers 7 Following
GI Cancer Institute a.. @GICancer
2K Followers 1K Following We raise funds for clinical research which improves gastro-intestinal cancer treatment and conduct research as the Australasian Gastro-Intestinal Trials Group.
артур шарае.. @Artur196524
70 Followers 515 Following
Mike @mike286347
87 Followers 5K Following
Sunny Lee @SunnyLe50585151
0 Followers 4 Following
Jam King @jamhoorking
46 Followers 221 Following
peterleipelt @peterleipelt
13 Followers 4 Following
Moonraker1 @the_moonraker_1
355 Followers 5K Following
Junk @MountainGoldX
244 Followers 313 Following Rally ‘round the family with a pocket full of shells 🇺🇸
Rajni Kohli @rajni_kohli_
18 Followers 172 Following
SciStories LLC @TeamSciStories
518 Followers 595 Following 🔬 Effective communications for bioscience 🌟 Amplifying research 🚀 #ScienceCommunications #WomanOwned
TralfamadoreJorge �.. @TralfamadoreJP
952 Followers 2K Following Metaverse Compounder + VIP's dad 😎 + Admiralty Lawyer ⚓️ + @Jason's Syndicate 🚀 + good friends ❤️
Evelyn @thyshoa39631
8 Followers 2K Following The pursuit of truth and knowledge and the struggle for it are one of the highest qualities of human beings
Paul l @Looknova
29 Followers 46 Following
PrismMarketView @PrismMarketView
4K Followers 2K Following The PRISM stock indexes track small/micro-cap companies across a diverse spectrum of industries including clean energy, biotech and next-gen tech.
ocky ocky @ockyocky1
43 Followers 124 Following
Gareeb Balla @GareebBalla
432 Followers 3K Following #Postdoctoral Fellow @uamshealth. Interested in the role of #Osteoclast- #Mitochondria and #Sirtuin- in skeletal #aging, stress, and inflammation.
Dalya Partners - Life.. @DalyaPartners
63 Followers 155 Following #Consulting expertise, capabilities & services for #biotech, #pharmaceutical, #MentalHealth & government #PublicHealth #pharma #neuroscience #healthcare
BRJ @bubbarayjr65
74 Followers 222 Following
Jeff @CyclingHiking
13 Followers 88 Following
Health Stocks News @health_stocks
2K Followers 241 Following Real-Time News, Market Data, Stock Quotes, Insider Trades, FDA Calendar, News Alerts, Stock Lists, Stock Screener, Heat Map @ https://t.co/Oqp6BRBKy2
Pharmalytics Group @pharmalyticsgrp
54 Followers 410 Following Pharmalytics Group is an independent health economics and outcomes research (HEOR) and market access consultancy.
BeiGene @BeiGeneGlobal
5K Followers 285 Following We’re a global oncology company bringing innovative medicines & making them more accessible to patients worldwide. Community guidelines: https://t.co/bZCHuaXk0s
Gastric Cancer Founda.. @GastricCancerFD
2K Followers 194 Following The Gastric Cancer Foundation (GCF) is dedicated to improving the lives of people affected by #stomachcancer and to working with researchers to find a cure.
Meredith Pelster @MeredithPelster
201 Followers 137 Following GI medical oncologist at SCRI Oncology Partners. Associate Program Director , GI Cancer Research Program at SCRI.
Sam Klempner @KlempnerSam
3K Followers 652 Following GI medical oncologist focusing on stomach and esophageal cancer research at Massachusetts General Hospital, Harvard Medical School
AACR @AACR
112K Followers 2K Following The mission of the American Association for Cancer Research is to prevent and cure cancer through research, education, communication, and collaboration.
Dana-Farber @DanaFarber
113K Followers 9K Following Dana-Farber Cancer Institute - a leading center for expert, compassionate cancer care and advanced research. Appts: 877-442-3324 | https://t.co/HvCwkLltic
Memorial Sloan Ketter.. @MSKCancerCenter
104K Followers 2K Following One of the world’s leading comprehensive cancer centers. To make an appointment: 877-871-9362
Doug Onsi @deonsi
553 Followers 171 Following CEO, Leap Therapeutics; Managing Director, HealthCare Ventures; fan of everything Boston, Michigan, Cornell and my kidsWelcome Dr. Schilsky! Excited to work with you to develop DKN-01 and build Leap.
We welcome Dr. Richard Schilsky to our board of directors. A pre-eminent oncologist with vast experience in clinical trials, academic research and regulatory process to guide us in the further development of DKN-01. investors.leaptx.com/news-releases/…
Very proud of the work of all my fellow Leapsters, our partner @BeiGeneGlobal, WAKING trial collaborator @Roche and the physicians and patients in our DKN-01 clinical trials being presented at #ESMO22.
We are excited to present new data from our DKN-01 gastric cancer clinical trials at #ESMO22. DisTinGuish: in combination with @BeiGeneGlobal’s tislelizumab and chemo in 1L. WAKING: in combination with @Roche’s atezolizumab in 2L/3L. investors.leaptx.com/news-releases/…
Excited to announce activation of our clinical trial targeting DKK1 as a strategy to activate NK cells and anti-tumor immunity in advanced prostate cancer! Thanks to Leap Therapeutics and @PCF_Science for supporting this study! prostatecancernewstoday.com/2019/02/28/lea…
Today concludes 'Emerging Data on the Role of Wnt Biology in Cancer' led by Roel Nusse and Bart Williams with funding by @LeapTherapeutic. Thanks to all participants; meeting agenda now on our website: bit.ly/2OgPvu0
Trends for United States
You might like
